A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles

• In: Poster Presentation
• At: Stockholm (Sweden) (2017)
• Type: Poster
• Poster code: P-B-055-Tuesday
• By: SOUSA, Flávia (i3S, INEB, Porto, Portugal)
• Co-author(s): Flávia Sousa: INEB, University of Porto, Porto, Portugal;i3S, University of Porto, Porto, Portugal;, International Iberian Nanotechnology Laboratory, Braga, Portugal;Instituto Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal;, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Porto, Portugal
  Andrea Cruz: International Iberian Nanotechnology Laboratory, Braga, Portugal
  Inês Mendes Pinto: International Iberian Nanotechnology Laboratory, Braga, Portugal
  Maria Teresa Neves-Petersen: Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark
  Bruno Sarmento: INEB, University of Porto, Porto, Portugal;i3S, University of Porto, Porto, Portugal
  
• Abstract:

  Backgrounds

  Monoclonal antibodies (mAbs) have deserved a remarkable interest for more than 40 years as a vital tool for the treatment of various diseases. Despite mAbs-based therapy have noteworthy interest, there are some limitations such multiples administrations by the intravenous route, short half-life, and short shelf-life.

  Aims

  Thus, the aim of
  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login